Category

News

ProMIS Neurosciences Announces Trading on OTCQB Venture Market

By | News

ProMIS Neurosciences Announces Trading on OTCQB Venture Market TORONTO, Ontario and CAMBRIDGE, Massachusetts, December 4, 2017 – ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its common shares have been approved for trading on the OTCQB® Venture Market (OTCQB) in…

Read More

ProMIS Neurosciences Announces Third Quarter 2017 Results

By | News

ProMIS™ Neurosciences, Inc. NEWS RELEASE TSX: PMN FOR IMMEDIATE RELEASE ProMIS Neurosciences Announces Third Quarter 2017 Results TORONTO, Ontario and CAMBRIDGE, Massachusetts November 13, 2017 – ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the…

Read More

ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer’s Disease

By | News

ProMIS™ Neurosciences, Inc. NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer’s Disease Narrated presentation of results available on ProMIS website TORONTO, Ontario and CAMBRIDGE, Massachusetts – October 17, 2017 – ProMIS…

Read More

ProMIS Neurosciences Provides Third Quarter Update for 2017

By | News

ProMIS™ Neurosciences, Inc. NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE ProMIS™ Neurosciences Provides Third Quarter Update for 2017 Updated corporate overview available on ProMIS website TORONTO, Ontario and CAMBRIDGE, Massachusetts – October 11, 2017 – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for…

Read More

ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference

By | News, Uncategorized

ProMIS Neurosciences, Inc. NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference Presentation highlights the use ProMIS’ proprietary discovery platform to identify novel therapeutic targets on misfolded proteins in multiple neurodegenerative diseases TORONTO, Ontario and CAMBRIDGE, Massachusetts…

Read More